Stockscreener 앱 받기
0.6815
0.85%
-0.015
전일 마감가:
$0.6965
열려 있는:
$0.7112
하루 거래량:
963.26K
Relative Volume:
1.13
시가총액:
$157.26M
수익:
-
순이익/손실:
$-179.82M
주가수익비율:
-0.3084
EPS:
-2.21
순현금흐름:
$-159.16M
1주 성능:
-10.31%
1개월 성능:
-25.02%
6개월 성능:
+3.07%
1년 성능:
-9.07%
1일 변동 폭
$0.68
$0.7199
1주일 범위
$0.6807
$0.78
52주 변동 폭
$0.4993
$1.60
Gossamer Bio Inc Stock (GOSS) Company Profile
명칭
Gossamer Bio Inc
전화
(858) 922-0718
주소
3013 SCIENCE PARK, SAN DIEGO, CA
GOSS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| GOSS | 0.6838 | 157.26M | 0 | -179.82M | -159.16M | -2.21 |
| VRTX | 449.19 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.15 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 599.00 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.91 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.97 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-05 | 재개 | Wedbush | Outperform |
| 2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-03-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 개시 | Guggenheim | Neutral |
| 2022-12-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-07 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | JP Morgan | Neutral |
| 2022-09-19 | 개시 | Wedbush | Outperform |
| 2022-04-18 | 개시 | Raymond James | Outperform |
| 2022-04-06 | 개시 | UBS | Buy |
| 2022-01-10 | 업그레이드 | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 재개 | Piper Sandler | Overweight |
| 2020-06-29 | 개시 | H.C. Wainwright | Buy |
| 2020-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-30 | 개시 | Berenberg | Buy |
| 2019-03-05 | 개시 | Barclays | Overweight |
| 2019-03-05 | 개시 | BofA/Merrill | Buy |
| 2019-03-05 | 개시 | Evercore ISI | Outperform |
| 2019-03-05 | 개시 | SVB Leerink | Outperform |
모두보기
Gossamer Bio Inc 주식(GOSS)의 최신 뉴스
All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy - Yahoo Finance
US Bancorp DE Makes New $39,000 Investment in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) - Yahoo Finance
Leerink Partnrs Raises Earnings Estimates for Gossamer Bio - Defense World
After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) - Yahoo Finance
HC Wainwright Increases Earnings Estimates for Gossamer Bio - MarketBeat
FMR LLC's Strategic Acquisition of Gossamer Bio Inc Shares - GuruFocus.com
Industry Analysts Just Made A Sizeable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Revenue Forecasts - Yahoo Finance
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Gossamer Bio Grants 183K Stock Options to New Hires at $0.88 Per Share | GOSS Stock News - StockTitan
Gossamer Bio (NASDAQ:GOSS) Earns Buy Rating from HC Wainwright - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Gossamer Bio Reports Revenue Growth Amid Strategic Collaborations - TipRanks
Gossamer Bio: Q3 Earnings Snapshot - Houston Chronicle
GOSSGossamer Bio, Inc. Latest Stock News & Market Updates - StockTitan
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now - The Manila Times
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Large Decline in Short Interest - Defense World
3 US Penny Stocks With Market Caps Under $900M To Consider - Simply Wall St
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
It makes sense and dollars to buy Gossamer Bio Inc (GOSS) stock - SETE News
Financial Fitness Check: Examining Gossamer Bio Inc (GOSS)’s Key Ratios - The Dwinnex
Gossamer Bio Inc (GOSS) rating initates by Oppenheimer - Knox Daily
Millennium Management LLC Sells 898,042 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Sold by Millennium Management LLC - MarketBeat
The Attractiveness of Investing In Gossamer Bio Inc (GOSS) is Growing - Knox Daily
Investor’s Delight: Gossamer Bio Inc (GOSS) Closes Weak at 1.02, Down -2.86 - The Dwinnex
GOSS underperforms with a -2.86 decrease in share price - US Post News
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Gossamer Bio Inc [NASDAQ: GOSS] Sees Decrease in Stock Value - Knox Daily
Marshall Wace LLP Boosts Position in Gossamer Bio, Inc. (NASDAQ:GOSS) - MarketBeat
Several Insiders Invested In Gossamer Bio Flagging Positive News - Yahoo Finance
Analyzing Northwest Biotherapeutics (OTCMKTS:NWBO) and Gossamer Bio (NASDAQ:GOSS) - Defense World
Navigating GOSS’s Stock Market Maze: Ups and Downs in 2023 - The InvestChronicle
A better buy-in window may exist right now for Gossamer Bio Inc (GOSS) - SETE News
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 5.8% in September - Defense World
Analysts review Gossamer Bio Inc’s rating - Knox Daily
GOSS (Gossamer Bio Inc) has impressive results - US Post News
A company insider recently sold 1,908 shares of Gossamer Bio Inc [GOSS]. Should You Sale? - Knox Daily
GoDaddy (NYSE:GDDY) PT Raised to $185.00 at Barclays - MarketBeat
It makes sense and dollars to buy Gevo Inc (GEVO) stock - SETE News
Gaining Ground: Gossamer Bio Inc (GOSS) Closes Lower at 0.99, Down -0.61 - The Dwinnex
NEA Management Company LLC Buys 2,255,025 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Keeping an Eye on Globus Medical Inc (GMED) After Insider Trading Activity - Knox Daily
Presenting on the Emerging Growth Conference 75 Day 2 on September 26 - GlobeNewswire
Analysts review Godaddy Inc’s rating - Knox Daily
A significant driver of top-line growth: Gossamer Bio Inc (GOSS) - SETE News
Is GlycoMimetics Inc (GLYC) a threat to investors? - US Post News
Globus Medical's (NYSE:GMED) investors will be pleased with their favorable 42% return over the last year - Yahoo Finance
Gossamer Bio Inc (GOSS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Gossamer Bio Inc 주식 (GOSS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hasnain Faheem | President & CEO |
Jun 21 '24 |
Buy |
0.67 |
372,000 |
250,282 |
5,408,073 |
| Giraudo Bryan | COO/CFO |
Jun 18 '24 |
Buy |
0.59 |
100,000 |
59,110 |
480,010 |
| Smith Robert Paul JR | Chief Commercial Officer |
Jun 17 '24 |
Buy |
0.60 |
25,000 |
15,050 |
25,000 |
| Christian Waage | EVP, Tech Ops and Admin |
Mar 27 '24 |
Sale |
1.16 |
6,430 |
7,430 |
585,934 |
| Giraudo Bryan | COO/CFO |
Mar 27 '24 |
Sale |
1.16 |
6,430 |
7,431 |
92,737 |
| Hasnain Faheem | President & CEO |
Mar 27 '24 |
Sale |
1.16 |
23,172 |
26,773 |
120,293 |
| Aranda Richard | Chief Medical Officer |
Mar 18 '24 |
Sale |
1.33 |
4,018 |
5,342 |
198,799 |
| Peterson Caryn | EVP, Regulatory Affairs |
Mar 18 '24 |
Sale |
1.33 |
4,018 |
5,343 |
49,833 |
1.80%
0.42%
자본화:
|
볼륨(24시간):